ALZHEIMER DISEASE: Solanezumab—prospects for meaningful interventions in AD?

    loading  Checking for direct PDF access through Ovid

Abstract

A treatment trial of the monoclonal anti-amyloid antibody solanezumab showed slight benefits in people with dementia due to mild Alzheimer disease. Drug effects on several neuropsychological testing outcomes were statistically significant, but the effect sizes were unlikely to manifest as meaningful functional benefits. Here, we discuss the implications and possible molecular underpinnings.

Related Topics

    loading  Loading Related Articles